Efficacy of Cindilizumab Plus XELOX Regimen in Advanced Gastric Cancer And Its Effect on Serum Tumor Markers
Objective:To investigate the curative effect of cindilizumab combined with XELOX regimen in patients with advanced gastric cancer and its influence on serum tumor markers.Methods:68 patients with advanced gastric cancer admitted to Qidong Hospital affiliated to Nantong University from January 2021 to March 2024 were ran-domly divided into control group and observation group,with 34 patients in each group.34 cases in the control group were treated with XELOX regimen,and 34 cases in the observation group were treated with sindilizumab on top of the control group..The curative effect、serum tumor markers、immune indexes and adverse reactions were compared between the two groups.Results:Comparing the objective remission rate and disease control rate of the two groups,the observation group was significantly higher than the control group,P＜0.05.Before treatment,the levels of blood tumor markers and immune function indexes in the two groups were compared,P＞0.05;After treat-ment,tumour markers in the observation group and the level of immune function index was better than that in the control group,P＜0.05.The incidence of adverse reactions between the two groups was compared,P＞0.05.Conclusion:Cindilizumab combined with XELOX can achieve good curative effect in the treatment of advanced gastric cancer,and can reduce the level of tumor markers and regulate the immune function of patients,and the ad-verse reactions can be controlled.
国家科技期刊平台
NSTL
万方数据
